Clinical Trial

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Protocol Amendment History 30 amendments
This ClinicalTrials.gov record has been amended 30 times since 2021-05-28; most recent amendment 2026-04-22.
Status change: Recruiting → Active, Not Recruiting 2025-12-17
Status change: Not Yet Recruiting → Recruiting 2021-06-17
Trial Details
NCT Number NCT04913285
Lead Sponsor Pierre Fabre Medicament
Conditions Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Enrollment 400 participants
Start Date 2021-08-04
Primary Completion 2028-11-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-27